{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:31:28Z","timestamp":1793716288061,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Head and neck squamous cell carcinoma (HNSCC) remains a prevalent and aggressive malignancy, characterized by a lack of targeted therapies and limited clinical benefits. Here, we conducted an optimized whole-genome CRISPR screen across five HNSCC cell lines aimed at identifying actionable genetic vulnerabilities for rapid preclinical evaluation as novel targeted therapies. Given their critical role in cancer, cyclin-dependent kinases (CDKs) were prioritized for further investigation. Among these, CDK7 was identified as an essential and targetable gene across all five cell lines, prompting its selection for in-depth functional and molecular characterization. Genetic and pharmacological inhibition of CDK7 significantly and consistently reduced tumor cell proliferation due to generalized cell cycle arrest and apoptosis induction. Additionally, CDK7 knockout (KO) and selective inhibitors (YKL-5-124 and samuraciclib) demonstrated potent antitumor activity, effectively suppressing tumor growth in HNSCC patient-derived organoids (PDOs), as well as in both cell line- and patient-derived xenograft (PDX) mouse models with minimal toxicity. Mechanistically, CDK7 inhibition led to a broad downregulation of gene sets related to cell cycle progression and DNA repair, and significantly reduced the transcription of essential genes and untargetable vulnerabilities identified by our CRISPR screen. These findings highlight CDK7 as a promising therapeutic target for HNSCC. Our study provides strong evidence of the robust antitumor activity of CDK7-selective inhibition in disease-relevant preclinical models, strongly supporting its progression to clinical testing.<\/jats:p>","DOI":"10.1038\/s41392-025-02452-z","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:03:46Z","timestamp":1762383826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Mar\u00eda","family":"Otero-Rosales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"\u00c1lvarez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"de Lux\u00e1n-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Del Marro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Pozo-Agundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Rodr\u00edguez-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Corte-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Granda-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00fal","family":"\u00c1lvarez-Teijeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Fern\u00e1ndez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Lorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-6542","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-0890","authenticated-orcid":false,"given":"Juan P.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-7648","authenticated-orcid":false,"given":"Konstantinos","family":"Tzelepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-8022","authenticated-orcid":false,"given":"George","family":"Vassiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-9488","authenticated-orcid":false,"given":"Juana Mar\u00eda","family":"Garc\u00eda-Pedrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-0337","authenticated-orcid":false,"given":"Francisco","family":"Hermida-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2452_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2452_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fonc.2017.00072","volume":"7","author":"A Argiris","year":"2017","unstructured":"Argiris, A. et al. Evidence-based treatment options in recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 7, 72 (2017).","journal-title":"Front Oncol."},{"key":"2452_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2452_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"2452_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567\u2013578 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2452_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2452_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N. Engl. J. Med 375, 1738\u20131748 (2016).","journal-title":"N. Engl. J. Med"},{"key":"2452_CR8","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2452_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(19)30405-X","volume":"20","author":"D Adkins","year":"2019","unstructured":"Adkins, D. et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 20, 1295\u20131305 (2019).","journal-title":"Lancet Oncol."},{"key":"2452_CR10","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.4161\/cc.26355","volume":"12","author":"MM Schachter","year":"2013","unstructured":"Schachter, M. M. & Fisher, R. P. The CDK-activating kinase Cdk7: taking yes for an answer. Cell Cycle 12, 3239\u20133240 (2013).","journal-title":"Cell Cycle"},{"key":"2452_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molcel.2013.04.003","volume":"50","author":"MM Schachter","year":"2013","unstructured":"Schachter, M. M. et al. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. Mol. Cell 50, 250\u2013260 (2013).","journal-title":"Mol. Cell"},{"key":"2452_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molcel.2007.02.003","volume":"25","author":"S Larochelle","year":"2007","unstructured":"Larochelle, S. et al. Requirements for Cdk7 in the assembly of Cdk1\/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25, 839\u2013850 (2007).","journal-title":"Mol. Cell"},{"key":"2452_CR13","doi-asserted-by":"publisher","first-page":"e1003546","DOI":"10.1371\/journal.pgen.1003546","volume":"9","author":"X Bisteau","year":"2013","unstructured":"Bisteau, X. et al. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4\/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genet. 9, e1003546 (2013).","journal-title":"PLoS Genet."},{"key":"2452_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle, S. et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 19, 1108\u20131115 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2452_CR15","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1158\/1078-0432.CCR-15-1104","volume":"22","author":"H Patel","year":"2016","unstructured":"Patel, H. et al. Expression of CDK7, Cyclin H, and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer. Clin. Cancer Res. 22, 5929\u20135938 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2452_CR16","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/0008-5472.CAN-16-2546","volume":"77","author":"B Li","year":"2017","unstructured":"Li, B. et al. Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer. Cancer Res. 77, 3834\u20133845 (2017).","journal-title":"Cancer Res."},{"key":"2452_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927140","volume":"12","author":"C Kuempers","year":"2022","unstructured":"Kuempers, C. et al. CDK7 is a prognostic biomarker for non-small cell lung cancer. Front Oncol. 12, 927140 (2022).","journal-title":"Front Oncol."},{"key":"2452_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41416-024-02589-8","volume":"130","author":"X Song","year":"2024","unstructured":"Song, X. et al. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. Br. J. Cancer 130, 1239\u20131248 (2024).","journal-title":"Br. J. Cancer"},{"key":"2452_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","volume":"30","author":"C Guarducci","year":"2024","unstructured":"Guarducci, C. et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer. Clin. Cancer Res. 30, 1889\u20131905 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2452_CR20","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1038\/s41388-019-0701-1","volume":"38","author":"P Lu","year":"2019","unstructured":"Lu, P. et al. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Oncogene 38, 3932\u20133945 (2019).","journal-title":"Oncogene"},{"key":"2452_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell 37, 37\u201354 e39 (2020).","journal-title":"Cancer Cell"},{"key":"2452_CR22","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/emboj.2012.94","volume":"31","author":"M Ganuza","year":"2012","unstructured":"Ganuza, M. et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 31, 2498\u20132510 (2012).","journal-title":"EMBO J."},{"key":"2452_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"2452_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nbt.2800","volume":"32","author":"H Koike-Yusa","year":"2014","unstructured":"Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267\u2013273 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2452_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1089\/crispr.2020.0137","volume":"4","author":"S Balderston","year":"2021","unstructured":"Balderston, S. et al. Diversification of the CRISPR toolbox: applications of CRISPR-Cas systems beyond genome editing. CRISPR J. 4, 400\u2013415 (2021).","journal-title":"CRISPR J."},{"key":"2452_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e516 (2017).","journal-title":"Cell"},{"key":"2452_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"2452_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193\u20131205 (2016).","journal-title":"Cell Rep."},{"key":"2452_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"2452_CR30","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184, 5357\u20135374.e5322 (2021).","journal-title":"Cell"},{"key":"2452_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"2452_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature06046","volume":"448","author":"D Santamaria","year":"2007","unstructured":"Santamaria, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811\u2013815 (2007).","journal-title":"Nature"},{"key":"2452_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes, R. C. et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat. Commun. 14, 4444 (2023).","journal-title":"Nat. Commun."},{"key":"2452_CR34","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/oncolo\/oyad215","volume":"29","author":"E Garralda","year":"2024","unstructured":"Garralda, E. et al. A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. Oncologist 29, e131\u2013e140 (2024).","journal-title":"Oncologist"},{"key":"2452_CR35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson, C. M. et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem. Biol. 26, 792\u2013803 e710 (2019).","journal-title":"Cell Chem. Biol."},{"key":"2452_CR36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel, H. et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol. Cancer Ther. 17, 1156\u20131166 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2452_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.medj.2023.04.003","volume":"4","author":"R Millen","year":"2023","unstructured":"Millen, R. et al. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Med 4, 290\u2013310.e212 (2023).","journal-title":"Med"},{"key":"2452_CR38","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1158\/1078-0432.CCR-22-2150","volume":"29","author":"AS Clark","year":"2023","unstructured":"Clark, A. S. et al. Phase II study of palbociclib (PD-0332991) in CCND1, 2, or 3 amplification: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) Subprotocol Z1B. Clin. Cancer Res. 29, 1477\u20131483 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2452_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang, Q., Bode, A. M. & Zhang, T. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 7, 58 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"2452_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-022-02443-w","volume":"41","author":"S Zeng","year":"2022","unstructured":"Zeng, S. et al. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. J. Exp. Clin. Cancer Res. 41, 241 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2452_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/cancers14030492","volume":"14","author":"T Jagomast","year":"2022","unstructured":"Jagomast, T., et al. CDK7 predicts worse outcome in head and neck squamous-cell cancer. Cancers 14, 492 (2022).","journal-title":"Cancers"},{"key":"2452_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2018.10.004","volume":"51","author":"L Jiang","year":"2019","unstructured":"Jiang, L. et al. Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma. Pathology 51, 74\u201380 (2019).","journal-title":"Pathology"},{"key":"2452_CR43","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MD.0000000000004764","volume":"95","author":"JN Rich","year":"2016","unstructured":"Rich, J. N. Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine 95, S2\u2013S7 (2016).","journal-title":"Medicine"},{"key":"2452_CR44","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1073\/pnas.1424171112","volume":"112","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc. Natl Acad. Sci. USA 112, 1839\u20131844 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2452_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.MCT-10-1120","volume":"10","author":"K He","year":"2011","unstructured":"He, K., Xu, T. & Goldkorn, A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol. Cancer Ther. 10, 938\u2013948 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"2452_CR46","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380\u20133409 (2020).","journal-title":"Nat. Protoc."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02452-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:03:47Z","timestamp":1762383827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02452-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2452"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02452-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.T. is a shareholder of and has received research funding from Storm Therapeutics Ltd. All the other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}